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Background: To retrospectively access the outcome and toxicity of a total skin electron beam therapy (TSEBT) in
patients with cutaneous lymphoma (CL) or leukemia.
Patients and methods: Treatment results of 25 patients (median age 63 years; 5 female, 20 male) with cutaneous
manifestations of advanced and therapy-refractory CL (n = 21; T-cell lymphomas n = 18, B-cell lymphomas n = 3)
stage IIB-IV or leukemia (n = 4; AML n = 2, CLL n = 1, PDC n= 1) treated between 1993 and 2010 were reviewed.
All patients were symptomatic. The median total dose was 29Gy, applied in 29 fractions of median 1 Gy each.
Results: The median follow-up was 10 months. Palliation was achieved in 23 patients (92%). A clinical complete
response was documented in 13 (52%) and a partial response in 10 patients (40%). The median time to skin
progression was 5 months (range 1–18 months) and the actuarial one-year progression-free survival 35%.
The median overall survival (OS) after the initiation of TSEBT was 10 months (range 1–46 months) and the actuarial
one-year OS 45%. TSEBT related acute adverse events (grade 1 or 2) were observed in all patients during the
treatment period. An acute grade 3 epitheliolysis developed in eight patients (32%). Long-term adverse events as
a hyperpigmentation of the skin (grade 1 or 2) were documented in 19 patients (76%), and a hypohidrosis in
seven patients (28%).
Conclusion: For palliation of symptomatic cutaneous manifestations of advanced cutaneous lymphoma or
leukemia, total skin electron beam therapy is an efficient and well tolerated considerable treatment option.
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Cutaneous lymphomas (CL) account for approximately
19% of extra-nodal non-Hodgkin’s lymphoma. The pre-
dominate form of cutaneous lymphoma in the United
States were T-cell lymphoma (CTCL) between 2001 and
2005, which count for approximately 71% of cases, cor-
responding to an incidence rate (IR) of 7.7/1.000.000
person-years [1]. The subgroup of Mycosis fungoides
(MF), which is a T-cell lymphoma primarily of the skin
and originating from CD4-positive T-helper cells, accounts* Correspondence: Henrik.Hauswald@med.uni-heidelberg.de
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reproduction in any medium, provided the orfor approximately 38% of cases [1]. The WHO-EORTC
classification for CL was published 2005 by Willemze
et al. and revised in 2010 by Turner et al. [2,3]. The ori-
ginal TNM-classification is found in Tables 1 and 2, but
has been revised in 2007 [4]. Extramedullary manifesta-
tions of acute myeloid leukaemia are rare, for example
Agis et al. reported an incidence of approximately 3% in
patients suffering from an acute myeloid leukaemia
(AML) [5]. Furthermore, the incidence of granulocytic sar-
coma (chloroma) in patients with AML is about 8% [6].
Leukocytic infiltrations to the skin could result in symp-
tomatic plaques and nodules. In CL the clinical appear-
ance includes initially uncharacteristic skin rashes andral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 classification of cutaneous T-cell lymphoma (CTCL)
T-classification Description
T0 Clinically and/or histopathologically suspicious lesions
T1 Limited plaques, papules, or eczematous patches
covering <10% of the skin surface
T2 Generalized plaques, papules, or erythematous patches
covering 10% or more of the skin surface
T3 Tumors, one or more
T4 Generalized erythroderma
N-classification
N0 No clinically abnormal peripheral lymph nodes;
pathology negative for CTCL
N1 Clinically abnormal peripheral lymph nodes;
pathology negative for CTCL
N2 No clinically abnormal peripheral lymph nodes;
pathology positive for CTCL
N3 Clinically abnormal peripheral lymph nodes;
pathology positive for CTCL
M-classification
M0 No visceral organ involvement
M1 Visceral involvement (must have pathology
confirmation and organ involved should be specified)
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by eventually ulcerating tumors and nodules, as well as
erythroderma. Patients might additionally suffer from
extensive pruritus, pain and superinfections, so adapted
treatments are necessary. Total skin electron beam ther-
apy (TSEBT) using rotational technique was described
by Podgorsak et al. and Kumar et al. [7,8]. Furthermore,
Funk et al. reported on the technique and setup used in
Heidelberg: rotational TSEBT is applied using two 6
MeV-electron beams being reduced to 4 MeV by a Lucite
moderator [9]. TSEBT using electron beam energies of
3–4 MeV results in a dose fall-off in the visceral tissue to
approximately 10% at 17 mm depth, allowing the appli-
cation of high therapeutic treatment doses within the
skin (approximately 80% dose at 5 mm depth) while
avoiding penetration to deeper tissue [7]. For treatment
of cutaneous manifestations from leukemia, for exampleTable 2 Staging system of cutaneous T-cell lymphoma
(CTCL) (original version)
Stage T N M
IA 1 0 0
IB 2 0 0
IIA 1,2 1 0
IIB 3 0,1 0
III 4 0,1 0
IVA 1-4 2,3 0
IVB 1-4 0-3 1leukemia cutis or chloroma, only a few reports on local
radiotherapy or TSEBT do exist and large series or pro-
spective studies are lacking [10-13]. This retrospective
single institution analysis is an update of previously
published data [9] and was performed to access outcome
and toxicity of TSEBT in patients with cutaneous mani-
festations of advanced, extensively pretreated and therapy-
refractory CL or leukemia to help finding ways to improve
prognosis, morbidity and mortality.
Patients and methods
Patient characteristics
Between 1993 and 2010, 25 patients with advanced,
pretreated and therapy-refractory CL stage IIB to IV or
cutaneous manifestations of leukemia were treated in
palliative intention with TSEBT at the Department of
Radiation Oncology of the University Hospital Heidel-
berg. Even though the underlying diseases were partially
different, the clinical situations of these patients as well
as clinical challenge in palliation were comparable and
therefore analyzed together. All patients were refractory
to extensive pre-treatment with topical and systemic
approaches as chemotherapy, interferon, and/or PUVA-
photochemotherapy. All patients were symptomatic with
hemorrhages, pruritus, pain and/or ulcerating skin mani-
festations. The median time interval between initial diag-
nosis of the underlying disease and initiation of TSEBT
was 2 years (range 0.5-8 years). Further characteristics
were listed in Table 3. Unfortunately, the retrospective
character of this analyses limits further specifications
of the underlying diseases. An example of lesions before
and in the first follow-up examination in a patient suf-
fering from stage IIB CL were seen in Figures 1 and 2.
Radiotherapy
Radiotherapy was performed as total skin electron beam
therapy and the patient standing in an upright position
on a rotating base being irradiated by two electron fields
with initial energies of 6 MeV that are reduced to 3.8
MeV by a Lucite moderator. Details on treatment setup
were published by Funk et al. [9]. It was our intention to
perform a conventional TSEBT applying a total dose of
30–35 Gy. The median total dose applied was 29Gy
(range 11–35 Gy), median single fraction size was 1 Gy
(range 1–1.5 Gy). Additionally, 9 patients received a local
boost irradiation using electron beams. During the course
of radiotherapy, all patients were treated as inpatients to
observe them closely and to avoid a tumor lysis syndrome.
Statistics
The data was analysed regarding overall survival (OS)
and skin-progression-free survival (PFS). Statistical ana-
lyses were carried out with SPSS statistical package
(SPSS Inc., Chicago, IL, U.S.A.) using log-rank test
Figure 1 An example of lesions before TSEBT in a patient
suffering from stage IIB CL.
Figure 2 The leasions from image 1 as seen in the first
follow-up examination.
Table 3 Characteristics of 25 patients with advanced and
therapy-refractory CL










T-cell lymphoma (CTCL) 17 68
B-cell lymphoma (CBCL) 4 16
Acute myeloic leukemia 2 8
(AML)
Chronic lymphatic leukemia (CLL) 1 4






n. a. 3 12
Hauswald et al. Radiation Oncology 2012, 7:118 Page 3 of 7
http://www.ro-journal.com/content/7/1/118(Mantel-Cox) and Kaplan-Meier’s estimation. Signifi-
cance was defined as p-value <0.05. All time estimates
began with the initiation of radiation treatment. Docu-
mented long-term side effects were classified according
to the RTOG/EORTC Late Radiation Morbidity Scoring
Scheme (Appendix IV, CTC Version 2.0). Approval of
the ethics committee Heidelberg was obtained.
Results
Response to treatment, tumor control and survival
The median follow-up time was 10 months (range 1–
46 months). Treatment response regarding palliation
with symptom relief, especially of pruritus and regression
of cutaneous lesions, was achieved in 23 patients (92%).
A clinical complete response was documented in 13
(52%) and a partial response in 10 patients (40%). The
median time to skin progression was 5 months (range 1–
18 months) and the actuarial six-months and one-year
skin-progression-free survival were 55% and 35%, respec-
tively (Figure 3). There were no statistically significant
differences (p = 0.076) in PFS between CTCL (mean PFS
8.4 months, 95% CI 5.3-11.5 months), CBCL (mean PFS
3.0 months, 95% CI 1.8-4.1 months) and leukemia
(mean PFS 13.5 months, 95% CI 10.6-16.4 months). The
median overall survival after the initiation of TSEBT was
10 months (range 1–46 months; Figure 4). The actuarial
one-, two- and three-year OS were 45%, 20% and 7%,respectively. In total 8 patients survived at least 20 months
after initiation of TSEBT despite advanced and therapy-
refractory disease as well as advanced age at time of TSEBT.
Adverse events
Treatment related acute adverse events as mild to mod-
erate fatigue, mild erythema, dry desquamation, mild
Figure 3 Kaplan-Meier-Estimation of progression-free survival.
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the treatment period and shortly after. None of the
patients suffered from tumor lysis syndrome. An acute
grade 3 epitheliolysis developed in eight patients (31%).
Two patients died due to tumor progression and organ
failure during the radiation treatment. One of these 2
patients suffered from a pneumonia finally causing fatal
renal failure, the other patient developed fatal renal fail-
ure due to a blast crisis during TSEBT. Furthermore, fol-
lowing long-term adverse events were documented
during follow-up visits: grade 1 or 2 hyperpigmentation
of the skin developed in 19 patients (76%), and seven
patients (28%) reported a hypohidrosis.
Discussion
We report the treatment results in 25 patients treated
with total skin electron beam therapy between 1993 and
2010 for cutaneous manifestations of advanced, exten-
sively pretreated and therapy-refractory cutaneous
lymphoma and leukemia. The overall treatment response
with 92% symptom relief, especially of the pruritus
and regression of cutaneous lesions, and 52% clinical
complete remissions as well as 40% partial remissions
demonstrate the efficacy in the setting of advanced and
otherwise therapy-refractory disease. In the daily routine,
treatment side effects as fatigue and skin reactions
seem manageable.A recent development to reduce the significant
treatment-related side effects is to identify a lower pos-
sible treatment dose while keeping the effective treat-
ment response. In this setting, Harrison et al. identified
102 patients treated for MF with low-dose (5-< 30Gy)
TSEBT between 1958 and 1995. Patients had stage clas-
sifications T2-T4. The overall response rates were dose
dependent with 90% in patients receiving 5 to <10 Gy
(n = 19), 98% in 10 to <20Gy and 97% in 20 to <30Gy
and efficacy measures as OS and PFS were comparable
[14]. In comparison to our results, these patients were
treated with TSEBT median 4 months after initial diag-
nosis; in our cohort, patients were extensively pretreated
and time from initial diagnosis to TSEBT was median
2 years. Besides this, the majority (51 patients) had T2
disease. The PFS was not given for the whole group, but
the subgroup with T3 and T4 disease and >/= 30 Gy
TSEBT had a median PFS of 2.9 years and 4.6 years,
respectively. Kamstrup et al. evaluated prospectively the
efficacy of low-dose (10Gy) TSEBT. Ten patients with
stage IB-IV MF were treated with 4 fractions of 1 Gy
each week to a total dose of 10Gy. Six patients had T2,
2 patients T3 and 2 patients T4 disease, all patients
received prior therapies. The median time from initial
diagnosis to TSEBT was 1 year. The achieved overall
response rate was 90% with a rate of CR as high as 70%.
Median PFS was 5.2 months. Treatment was well
Figure 4 Kaplan-Meier-Estimation of overall survival.
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tion (33%) as most common side effects [15]. In com-
parison to our data, the overall response rates as well as
PFS are comparable; however the number of patients
with limited disease is relatively high in this study and
one would have expected better results in T2 stage.
An actual publication by Lindahl et al. reviewed 35
patients with CTCL treated with TSEBT in Denmark
between 2001 and 2008. Almost all patients had previous
treatments and 40% of patients had T2 disease. The me-
dian follow-up time was 7.6 months and 25 patients were
treated with high-dose (30 Gy) TSEBT and 10 patients
in a low-dose (4 Gy) protocol. The group of patients
with low-dose TSEBT had inadequate treatment response
(CR in 10%) compared to higher-doses (26–30 Gy in
1 Gy fractions; CR in 68%). Overall, 28% showed progres-
sive disease, 22.2% in T2 and 35.7% in T3 stage. Median
time to progression was 9 months. Side effects related to
TSEBT were documented in 88% of patients, including
erythema and ulceration in 80%. The most common
long-term side effect was alopecia (44%), dry skin (36%),
hyperpigmentation (28%), ocular irritation (24%) and tem-
porary loss of finger nails (16%). Furthermore, 2 patients
developed basal cell carcinoma and one patient a squa-
mous cell carcinoma. However, in 1 of these 3 patients,
PUVA was administered previously, while one other
of these 3 patients previously received topical nitrogen
mustard. The authors concluded that CTCLs are highlyradiosensitive and TSEBT offers significant palliation,
but relapse is common and it remains unclear whether
prior treatment to TSEBT prolongs the effects of TSEBT
[16]. Navi et al. reported on 180 patients treated with
TSEBT as a first-line therapy for stage T2 and T3 MF,
additionally, many patients received HN2 topically as an
adjuvant treatment. All analyzed patients received a total
dose of 30 Gy or more, in several patients a second
course of TSEBT was necessary. Sixty-three percent
achieved a clinical complete remission (CCR), the CCR
rates for T2 and T3 stage were 75% and 47%, respect-
ively. Furthermore, freedom from relapse (FFR) was
longer in patients with T2 than T3 disease. Median
duration of response was 29 months in T2 stage and
9 months in T3 stage. In multivariate analysis T2-stage
and fewer prior therapies were associated with improved
FFR. The 5-year overall survival was 63%, again, multi-
variate analysis showed T2-stage and lower count of
prior therapies as well as younger age to be prognostic.
Regarding side effects, nearly all patients were reported
to have mild to moderate dermatitis, alopecia, nail dys-
trophy and xerosis [17]. In comparison, our results have
lower survival rates and earlier tumor progression, which
might be explained by the different patient selection. In
our department, we normally see patients with advanced,
extensively pretreated and therapy-refractory CL (includ-
ing symptomatic patients with M1 disease), and TSEBT
is not commonly used as a first-line therapy. So the
Table 4 Overview of literature
Author Stage Type of radiation
treatment
Total dose Treatment response PFS OS
Lindahl et al. [16] T1 5.7% TSEBT High-dose (30 Gy) n = 25 High-dose: CR 68% 9 months median n. a.
T2 40% Low-dose (4 Gy) n = 10 Low-dose:CR 10%
T3 48.6%
T4 5.7%
Navi et al. [17] T2 57% TSEBT (+/- HN2) 36 Gy (range 30-40 Gy) T2: CCR 75% T2: 8.5 years T2: 10.9 years
T3 43% T3: CCR 47% T3: 2.9 years T3: 4.7 years
Kamstrup et al. [16] T2 n = 6 TSEBT 10 Gy OR 90% median response duration
5.2 months
n. a.
T3 n = 2 CR 30%
T4 n= 2
Chinn et al. [18] T2 n = 55 TSEBT (+/- HN2) Mostly 36 Gy T2: CR 76% Freedom from recurrence
at 1 year 41%
T2: 10.7 years
T3 n = 27 T3: CR 44% T3: 3.6 years
This Analysis IIB n = 4 TSEBT Median 29 Gy OR 92% 5 months 10 months
III n = 1 CCR 52%
IVA n = 10
IVB n= 7
Abbreviations: TSEBT total skin electron beam therapy, CR complete remission, CCR clinical complete remission, OR overall response, PFS progression free survival,
OS overall survival.
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chemotherapies and/or PUVA-photochemotherapy and
are refractory to those. As Navi and colleagues reported,
prior treatments reduced in their multivariate analysis
the possibility of response to TSEBT [17]. Possibly native
lymphoma cells respond better to TSEBT, which might
explain the limited PFS in our analysis in comparison to
e. g. Navi and colleagues. Furthermore, the stage of dis-
ease as well as extension of the lesions might play a rele-
vant role. The patient group in our analysis included 10
patients in stage IVA disease and 7 patients in stage IVB
disease, which were commonly not found in previous
reports. An overview of the literature is found in Table 4.
In 2009 Neelis and co-workers published results on 18
patients with CBCL treated with palliative low-dose
involved-field (IF) radiotherapy (4 Gy in 2 fractions) and
31 patients with MF treated with 4 Gy, later with 8 Gy
in 2 fractions. In total 126 lymphoma sites were treated.
All patients were previously treated with different
approaches, 15 patients have already had TSEBT. In the
group of patients with CBCL, the rate of complete
remission (CR) was 75% (33/44 lesions). In patients suf-
fering from CTCL and MF, the remission rate after
application of 2 x 2 Gy was disappointing (70% failed
to achieve a CR), so the treatment dose was increased
to 2 x 4 Gy and a CR rate of 92% (60/65 lesions) was
achieved. According to the authors, high-grade side
effects were not seen. In conclusion, the authors recom-
mended low-dose IF radiotherapy as standard treatmentin patients with cutaneous lymphoma, with the option
of re-irradiation at progression [19]. From our point
of view, this concept of low-dose IF-RT seems to be an
option in localized CL, or in the situation of localized
recurrence after TSEBT.
Literature on cutaneous manifestations of leukemia,
e. g. leukemia cutis is very rare. Pepek and colleagues
reported on 2 pediatric patients treated with TSEBT
and recommended the consideration of TSEBT for pal-
liation [11]. Furthermore, Rubin et al. concluded in a
case report on a pediatric patient treated with TSEBT
for leukemia cutis, that TSEBT is feasible and poten-
tially effective [10]. Our experience supports the feasibil-
ity of TSEBT in cutaneous manifestations in leukemia,
especially in palliative situations.
Conclusion
For palliation of symptomatic cutaneous manifestations
of advanced, PUVA- and chemotherapy-refractory cuta-
neous lymphoma or leukemia, total skin electron beam
therapy is an efficient and well tolerated considerable
treatment option.
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